冷冻消融术：一种有前途的低风险乳腺癌非手术治疗方法。

Cryoablation: A promising non-operative therapy for low-risk breast cancer.

机构信息

Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, 79430, USA.

Texas Tech University Health Sciences Center, Breast Center of Excellence, Lubbock, TX, 79430, USA.

出版信息

Am J Surg. 2021 Jan;221(1):127-133. doi: 10.1016/j.amjsurg.2020.07.028. Epub 2020 Aug 1.

DOI:10.1016/j.amjsurg.2020.07.028

PMID:32788081

Abstract

BACKGROUND

The aim of this study was to evaluate the feasibility of cryoablation for early-stage low-risk breast cancer without tumor resection.

METHODS

Women diagnosed with ER+, PR+, and HER2-infiltrating ductal carcinomas ≤1.5 cm were treated with cryoablation. The non-surgical procedure used a Visica® 2 Treatment System with ultrasound guidance for ablation of the tumor with a 1 cm margin. Patients were monitored at 6-month intervals by MRI, mammogram, and ultrasound.

RESULTS

Twelve patients with unifocal breast cancer were treated with cryoablation for local control without follow-up tumor resection. All patients received adjuvant endocrine therapy, and none had radiation. The median follow-up was 28.5 (range = 4-41) months with 11 patients having at least one six-month follow-up. All imaging modalities showed complete ablation of target zone 11/11 (100%). Four patients (33.3%) have been followed up for ≥ 2 years with no local failure or residual disease.

CONCLUSION

Cryoablation of early-stage low-risk (ER+, PR+, and HER2-) breast cancer is a safe alternative to surgery.

摘要

背景

本研究旨在评估不进行肿瘤切除的情况下，对早期低危乳腺癌进行冷冻消融术的可行性。

方法

对 ER+、PR+和 HER2-浸润性导管癌≤1.5cm 的女性进行冷冻消融术治疗。非手术过程采用 Visica®2 治疗系统，在超声引导下对肿瘤进行消融，消融边界为 1cm。患者每 6 个月通过 MRI、乳房 X 光片和超声进行监测。

结果

12 例单发病灶乳腺癌患者接受冷冻消融术治疗，局部控制未行后续肿瘤切除术。所有患者均接受辅助内分泌治疗，无放疗。中位随访时间为 28.5（范围=4-41）个月，11 例患者至少有一次 6 个月随访。所有影像学检查均显示 11/11（100%）靶区完全消融。4 例（33.3%）患者的随访时间≥2 年，无局部复发或残留疾病。